Breadcrumb

James L. Gulley, M.D., Ph.D.

James L. Gulley, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Dr. Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the NCI. These innovative, investigator-initiated studies involve the use of cancer immunotherapy to (a) initiate immune responses, (b) expand immune responses and/or (c) allow the immune responses to be effective within the tumor microenvironment.

In addition to his role as the CIO Co-Director, Dr. James L. Gulley is also Director of the Medical Oncology Service, Office of the Clinical Director.

Areas of Expertise

1) immunotherapy 2) therapeutic cancer vaccines 3) immune checkpoint inhibitors 4) prostate cancer 5) clinical trials 6) combining immunotherapy with other therapies

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 

Clinical Trials

Publications

Selected Key Publications

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.
Clin Cancer Res. 24(6): 1287-1295, 2018. [ Journal Article ]

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, Mega AE, Britten CD, Ravaud A, Mita AC, Safran H, Stinchcombe TE, Srdanov M, Gelb AB, Schlichting M, Chin K, Gulley JL.
J Clin Oncol. 35(19): 2117-2124, 2017. [ Journal Article ]

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL.
Lancet Oncol. 13: 501-8, 2012. [ Journal Article ]

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Abdul Sater H, Marté JL, Donahue RN, Walter B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M, Harmon S, Turkbey IB, Choyke P, Schlom J, Dahut WL, Madan RA, Pinto PA, Gulley JL*
J ImmunoTher Cancer. 8: e000655, 2020. [ Journal Article ]

Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Galceran JC, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW
J Clin Oncol. 37: 1051-1061, 2019. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Adjunct Investigator
Clint Allen, M.D.
Adjunct Investigator
Nyall London, M.D., Ph.D.
Adjunct Investigator
Isaac Brownell, M.D., Ph.D.
Clinical Collaborator
Marc Theoret, M.D.
Clinical Research Coordinator
Jennifer Marte, M.D.
No photo
Physician Assistant
Amy Hankin, PA-C, MMSc
Physician Assistant
Lauren Skeffington, P.A.
Nurse Practitioner
Meg Kenyon, N.P.
Nurse Practitioner
Monique Williams, N.P.
Research Nurse
Erin Ferraro, R.N.
Research Nurse
Michell Manu, R.N.
Clinical Research Associate II
Manuk Manukyan
Biologist
Ling Zhang, Ph.D.
Postdoctoral Fellow
Andrew Sinkoe, Ph.D.
Research Assistant
Zulmarie Franco
Research Assistant
Alex Kuznetsov
Postbaccalaureate Fellow
Shania Bailey
Special Volunteer
Christopher Heery, M.D.
Research Assistant
Terri Larus
No photo
Medical Officer
Dimana Dimitrova, MD